Xiao Y, Zeng FY, Chen ZY, Zhao F, Sun JL. Advances in mesenchymal stem cell-based therapies for recurrent spontaneous abortion. World J Stem Cells 2025; 17(8): 108695 [DOI: 10.4252/wjsc.v17.i8.108695]
Corresponding Author of This Article
Jing-Li Sun, Chief Physician, Department of Obstetrics and Gynecology, General Hospital of Northern Theater Command (Heping Campus), No. 5 Guangrong Street, Heping District, Shenyang 110000, Liaoning Province, China. zg3416@sina.com
Research Domain of This Article
Obstetrics & Gynecology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Stem Cells. Aug 26, 2025; 17(8): 108695 Published online Aug 26, 2025. doi: 10.4252/wjsc.v17.i8.108695
Advances in mesenchymal stem cell-based therapies for recurrent spontaneous abortion
Yi Xiao, Fan-Yu Zeng, Zhen-Yu Chen, Feng Zhao, Jing-Li Sun
Yi Xiao, Fan-Yu Zeng, Zhen-Yu Chen, Department of Obstetrics and Gynecology, General Hospital of Northern Theater Command, Shenyang 110000, Liaoning Province, China
Feng Zhao, Department of Basic Medical, China Medical University, Shenyang 110000, Liaoning Province, China
Jing-Li Sun, Department of Obstetrics and Gynecology, General Hospital of Northern Theater Command (Heping Campus), Shenyang 110000, Liaoning Province, China
Co-first authors: Yi Xiao and Fan-Yu Zeng.
Author contributions: Xiao Y and Zeng FY contributed equally and share first authorship. Xiao Y and Zeng FY authored the manuscript’s initial draft; Chen ZY and Zhao F contributed to review and editing; Sun JL conceived, evaluated, and revised this paper. All authors read and approved the final manuscript.
Supported by the Natural Science Foundation of Liaoning Province, No. 2024-MSLH-525.
Conflict-of-interest statement: The authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jing-Li Sun, Chief Physician, Department of Obstetrics and Gynecology, General Hospital of Northern Theater Command (Heping Campus), No. 5 Guangrong Street, Heping District, Shenyang 110000, Liaoning Province, China. zg3416@sina.com
Received: April 21, 2025 Revised: May 29, 2025 Accepted: July 3, 2025 Published online: August 26, 2025 Processing time: 122 Days and 16.8 Hours
Abstract
Young women’s physical and mental health is seriously impacted by recurrent spontaneous abortion (RSA), a prevalent obstetric complication that is becoming more commonplace worldwide. Therefore, a thorough investigation into the pathophysiology of RSA and the development of novel therapeutic strategies are imperative. Recent developments suggest that mesenchymal stem cell (MSC)-based therapies may be viable for addressing RSA. Through a variety of mechanisms, the immunological circumstances at the maternal-fetal contact can be altered, including regulating immune cell homeostasis, enhancing immune tolerance, alleviating inflammatory responses, promoting angiogenic processes, and promoting tissue regeneration. MSCs exhibit a remarkable capacity for multi-differentiation that could enhance pregnancy outcomes. This article provides compelling studies supporting the efficacy of MSC-based therapies in improving pregnancy outcomes in women with RSA.
Core Tip: The reproductive health of women of childbearing age is significantly impacted by recurrent spontaneous abortion. Although there are several therapeutic options available today, the curative efficacy is unsatisfactory. By controlling immunological factors, mesenchymal stem cell therapy is one possible treatment option that can enhance pregnancy outcomes. Mesenchymal stem cell treatment and its associated mechanisms are briefly explained in this article.
